Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

2016, News

Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

N-of-One to Identify Treatment Strategies and Clinical Trial Opportunities for Patients based on Inivata’s ctDNA Liquid Biopsy Analysis

Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, Inc., a precision medicine oncology decision support company, are pleased to announce a new partnership to support analysis of patient cases for Inivata’s InVision® liquid biopsy product line.   This partnership will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information at their fingertips.

Inivata’s revolutionary approach to ctDNA analysis delivers industry leading sensitivity across a broad panel of clinically relevant genomic alterations.  The Next-Generation Sequencing-based method utilizes eTAm-Seq™, a proprietary amplification process, prior to sequencing and advanced analytical methods that enables the separation of true cancer mutations from background noise. The collaboration with N-of-One will provide each physician with an individualized liquid biopsy report based on their cancer patient’s unique genomic signature.  N-of-One’s oncologists and Ph.D. scientists will also provide the analysis needed to assess current treatments, analyze potential novel mutations and allow the oncologists to make more informed decisions for treatment strategies. Inivata has also recently announced the launch of a large-scale, prospective clinical validation study in non-small cell lung cancer and additional studies are currently underway.

Michael Stocum, Chief Executive Officer at Inivata, said: 

“N-of-One’s experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise.  We are excited to access their capabilities to ensure we provide physicians with the most actionable information in our easy to interpret report.”

N-of-One will support Inivata’s liquid biopsy assay by providing oncologists and pathologists with the most relevant oncology treatment options through the analysis of each patient’s unique molecular profile.  The N-of-One solution will integrate the interpretation of multiple molecular tests on a patient to provide a comprehensive view of the cancer and, leveraging N-of-One’s proprietary database, will identify individualized treatment options, including clinical trials for consideration by the oncologist.  N-of-One’s experience in oncology, and specifically liquid biopsies, makes them uniquely capable of interpreting the Inivata liquid biopsy test.

Chris Cournoyer, CEO of N-of-One, said: 

“We are pleased to partner with Inivata in support of the launch of their revolutionary ctDNA platform capabilities. Pairing Inivata’s highly sensitive analysis of actionable mutations with N-of-One’s ability to analyze the data of novel mutations has the potential to help guide more personalized treatment decisions for patients prior to and throughout the cancer care continuum.”


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.


Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US) +44 (0)20 3709 5700, +1 516 503 0271


Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News

LinkedIn tracking code Twitter tracking code